PARP Inhibitors and Immunotherapy in Gynecologic Cancer - prIME Oncology
prIME Downloadable Slides
prIME Downloadable Slides

PARP Inhibitors and Immunotherapy in Gynecologic Cancer

Novel Therapies to Improve Patient Outcomes

Not a member of My prIME? Join now for instant access.

Learn from the experts about current and emerging therapies for gynecologic malignancies. Topics include PARP inhibition and immunotherapeutic approaches for ovarian, cervical, and endometrial cancers.

Downloadable Slides

Downloadable Slides

Release Date

Release Date

Dec 17, 2018

Expiration Date

Dec 17, 2019

Featured Expert

  • Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology (US Oncology Network)
    University of Arizona College of Medicine-Phoenix, Creighton University School of Medicine at St Joseph's Hospital, Phoenix, Arizona, United States

Featured Topic

PARP inhibition and immunotherapeutic approaches for ovarian, cervical, and endometrial cancers

This activity is intended for gynecologic oncologists, medical oncologists, oncology nurses, and other members of the cancer care team involved in the management of gynecologic malignancies.

After successful completion of this educational activity, participants should be able to:

Physicians:

  • Develop treatment strategies using PARP inhibitors for patients with ovarian cancer
  • Analyze efficacy and safety data on checkpoint inhibitors, alone and in combination with other agents, including PARP inhibitors, for the treatment of ovarian cancer and cervical cancer
  • Discuss efficacy and safety data as well as ongoing clinical trials evaluating checkpoint inhibitors and PARP inhibitors for the treatment of endometrial cancer

Nurses:

  • Describe currently approved targeted therapy options for patients with ovarian cancer
  • Discuss the appropriate use of PARP inhibitors and checkpoint inhibitors for ovarian, endometrial, and cervical cancers, and incorporate strategies to communicate expectations of efficacy and safety to patients

This educational activity is supported by grants from AstraZeneca; Clovis Oncology; Merck and Co, Inc.; and TESARO, Inc.

Enduring Materials From a Certified Activity

This enduring material, derived from a certified live event, contains content that is evidence-based, balanced, and free of commercial bias. While the content was planned and implemented by prIME Oncology for a certified live event, this activity does not offer continuing education credit.

Provider

This activity is provided by prIME Oncology.

Disclosure Information

Disclosure of Relevant Financial Relationships

prIME Oncology assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. Any potential conflicts of interest that are identified are thoroughly vetted by prIME Oncology for fairness, balance, and scientific objectivity of data, as well as patient care recommendations. prIME Oncology is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial entity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:

Dr Monk, MD, has disclosed that he has received consulting fees from AbbVie; Advaxis; Amgen; AstraZeneca; Biodesix; Clovis; Genmab; Gradalis; ImmunoGen; Immunomedica; Incyte; Janssen/Johnson&Johnson; Mateon (formerly Oxigene); Merck; Myriad; Perthera; Pfizer; Precision Oncology; Puma; Roche/Genentech; Samumed; Takeda; Tesaro, Inc.; and VBL. He has also received honoraria for promotional speaker’s bureaus from AstraZeneca; Clovis; Janssen/Johnson&Johnson; Roche/Genentech; and Tesaro, Inc.

The employees of prIME Oncology have disclosed:

  • Robert Coleman, MD, FRCP, FRCPE (medical director content reviewer/planner) – consulting fees for advising on clinical trial protocol development from Amgen, Astellas, and Boehringer Ingelheim; intellectual property rights as co-inventor and patent holder of biomarker under development by Inbiomotion; independent medical education lectures at symposia supported by Amgen, Eisai, and Genomic Health; and travel expenses from Amgen for presentation of clinical trial data at ASCO 2018 conference.
  • Angela Zimmermann, PhD (scientific content reviewer/planner) – no relevant financial relationships
  • Brooke P. Balun, MSN, APRN-BC, AOCNP (lead nurse planner) – no relevant financial relationships
  • Susan McKinney (editorial content reviewer) – no relevant financial relationships

Disclosure Regarding Unlabeled Use

This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.